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Abstract
Background: Portal vein (PV) resection is used increasingly in pancreatic resections. There is no agreed
policy regarding anticoagulation.
Methods: A systematic review was performed to compare studies with an anticoagulation policy (AC+)
to no anticoagulation policy (AC−) after venous resection.
Results: There were eight AC+ studies (n = 266) and five AC− studies (n = 95). The AC+ studies included
aspirin, clopidogrel, heparin or warfarin. Only 50% of patients in the AC+ group received anticoagulation.
There were more prosthetic grafts in the AC+ group (30 versus 2, Fisher's exact P < 0.001). The overall
morbidity and mortality was similar in both groups. Early PV thrombosis (EPVT) was similar in the AC+
group and the AC− group (7%, versus 3%, Fisher's exact P = 0.270) and was associated with a high
mortality (8/20, 40%). When prosthetic grafts were excluded there was no difference in the incidence of
EPVT between both groups (1% vs 2%, Fisher's exact test P = 0.621).
Conclusion: There is significant heterogeneity in the use of anticoagulation after PV resection. Overall
morbidity, mortality and EPVT in both groups were similar. EPVT has a high associated mortality. While we
have been unable to demonstrate a benefit for anticoagulation, the incidence of EPVT is low in the
absence of prosthetic grafts.
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Introduction
Portal vein involvement in pancreatic cancer historically repre-
sented unresectable disease.1,2 Numerous contemporary reports
have highlighted acceptable morbidity, mortality and respectable
survival outcomes from venous resection provided an R0 resec-
tion is performed.3–8 Pancreatic adenocarcinoma with portal vein
involvement is no longer a contraindication to resection.9 The
clincher of unresectable disease now lies in superior mesenteric
arterial (SMA) invasion and resectability has now shifted to clear-
ance of the medial or SMA margin to facilitate an R0 resection
when combined with a venous resection.10
There are several techniques of performing mesentericoportal
vein resection and reconstruction. These include tangential or
lateral wedge venous resections with a non-occlusive side biting
vascular clamp, and where a more extensive length of vein is
resected this may be reconstructed primarily with an end-to-end
anastomosis or with a venous or prosthetic graft. In the latter,
portal vein clamping is required for the duration of the anasto-
mosis, which may lead to bowel oedema that may complicate the
subsequent pancreatico-enteric anastomosis. To prevent this
some centres perform superior mesenteric arterial occlusion,
and several Japanese centres have described the use of anti-
thrombogenic bypass catheters to prevent portal congestion or
hepatic ischaemia.11 In view of the vast differences in technique,
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we can expect significant heterogeneity in the population of
patients undergoing venous resection in the literature. To add to
this, several major Eastern centres perform arterial resections in
addition to venous resection, which make comparisons between
Eastern and Western patients difficult.12
Portal vein resection and clamping would intuitively be associ-
ated with an increased risk of portal vein thrombosis compared
with patients not undergoing venous resection. The risk of venous
thrombosis after a PV/SMV resection is estimated to be as high as
21–26% in some series.13–15 There appears to be no published
guidelines regarding anticoagulation after a venous resection with
a pancreatic resection and no current systematic review address-
ing this question.
The aim of this study was to review the different published
anticoagulation policies and outcomes of patients with and
without anticoagulation after a venous resection with a pancreatic
resection, with special reference to early portal vein thrombosis.
Methods
Study protocol
This systematic review followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines16
(Fig. 1). Three databases (MEDLINE from 1946, PubMed from
1946, and EMBASE from 1949) were searched to June 2013. The
search terms included ‘pancreatectomy OR pancreaticoduo-
denectomy’, ‘portal vein OR mesenteric vein’, and ‘resection
OR reconstruction’. A search for unpublished literature was not
performed.
Study selection
The studies that were included described patients that underwent
a pancreatic resection (pancreaticoduodenectomy, distal pancrea-
tectomy and total pancreatectomy) and a venous resection (portal
and/or superior mesenteric vein). Studies were only included if
they described a policy with respect to anticoagulation, of either
administering this or not administering this. This resulted in two
groups of publications, those with a policy of administering
anticoagulation (AC+) and those with a policy of not administer-
ing anticoagulation (AC−). Studies that described an extended
pancreatic resection, including an arterial resection involving the
celiac axis or SMA in combination with venous resection were
excluded. Studies that included an arterial resection alone without
a portal vein resection were excluded from this review.
Data extraction
Data extraction was done using a standardized data extraction
form. Information collected included the year of publication,
country of origin, number of pancreatic resections, number of
cases of venous resection, overall morbidity, mortality, incidence
of bleeding, re-operations and portal vein thrombosis.
Anticoagulation
Anticoagulation (AC) was defined as the use of heparin, warfarin
and included antiplatelet use such as aspirin and clopidogrel in
the immediate post-operative period, irrespective of the duration.
Although the purpose of this study was to assess anticoagulation
beyond standard thromboprophylaxis, some patients in the
anticoagulation group received only routine thromboprophylaxis.
The dosing and duration of these anticoagulation is further elabo-
rated in Table 1.
Intra-operative techniques
We have reported the practice of intra-operative heparinization in
each of the studies and the practice of superior mesenteric artery
occlusion at the time of venous anastomosis to prevent congestion
and intestinal oedema in Tables 1 and 2.
Venous resection and reconstruction
Venous resection included tangential and segmental resections
Tangential venous resections are lateral wedge resections of the
portal vein (PV) or SMV or the SMV-PV confluence. Segmental
venous resections involved resection of a cyclindrical portion of
the portal vein, superior mesenteric vein or mesentericoportal
confluence. Reconstruction after a tangential or segmental venous
resection was with a primary repair or with the use of a graft
(venous or prosthetic).17 We have defined the type of venous
resection used in these studies in Tables 1 and 2.
Portal vein thrombosis
The diagnosis of portal vein thrombosis was within 30 days, and is
termed early portal vein thrombosis (EPVT). The basis for the
diagnosis of EPVT varied between studies, but invariably used a
combination of clinical, biochemical and imaging studies includ-
ing Doppler ultrasound.
Statistical analysis
The data have been compared as descriptive statistics, with patient
demographic and clinical characteristics reported as percentages
for discrete characteristics. All P-values calculated were two-tailed;
the alpha level of significance was set at 0.05. Analysis was done on
an ‘intention-to-treat’ basis. Fisher’s exact test was used for statis-
tical analysis of categorical variables.
Results
Thirteen studies were included in this review. Eight studies (n =
266 patients) described a policy for anticoagulation after venous
resection (AC+ group, Table 1).14,15,18–23 There were five studies
(n = 95 patients) that described a policy of no post-operative
anticoagulation (AC− group, Table 2).24–28
Pancreatic resection
There was no significant difference between the two groups for the
types of pancreatic resection. The AC+ group had similar propor-
tions of pancreatoduodenectomies (242/266, 91% versus 86/95,
91%) and total pancreatectomies (14/266, 5% versus 9/95, 9%
692 HPB
HPB 2014, 16, 691–698 © 2013 International Hepato-Pancreato-Biliary Association
Fisher’s exact P = 0.223). The only distal pancreatectomies were in
the AC+ group (10/266, 4%) (Table 3).
Venous resection and reconstruction
There was a higher proportion of tangential resections in the AC+
group (147/266, 55%) compared with the AC− group (7/95, 7%
Fisher’s exact P < 0.001). There was a correspondingly lower pro-
portion of segmental resections in the AC+ group (119/266, 45%)
compared with the AC− group (88/95, 93% Fisher’s exact P <
0.001) (Table 3).
In regards to reconstruction there was a similar proportion of
tangential resections with primary venous closure without use of
a patch graft in the AC+ group (134/147, 91%) compared with the
AC− group (6/7, Fisher’s exact P = 0.494). There were fewer seg-
mental resections with primary end-to-end venous anastomosis
without graft use in the AC+ group (71/119, 60%) compared with
the AC− group (66/88, 75% Fisher’s exact P = 0.026).
There was no difference between the two groups with respect to
the proportion of patients who had some form of graft (venous
or prosthetic) (AC+ group 61/265, 23% compared with the
AC− group 23/95, 24% Fisher’s exact P = 0.888). There were
Records identified through
database searching
(n = 1586)
Additional records identified
through other sources
(n = 0)
Records after duplicates removed
(n = 897)
Records screened
(n = 897)
Records excluded
(n = 859)
Full-text articles excluded
(n = 23)
Debate article n = 1
Technique paper n = 1
Extended pancreatectomy with
celiac or SMA resection n = 3
Hepatic artery resection
without PVR included in study
n = 1
Review article n = 5
Survival study n = 2
No post-operative
anticoagulation policy
mentioned n = 7
Timing of post-op
anticoagulation unclear n = 1
Correspondence n = 1
Not relevant n = 1
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Figure 1 Flow chart showing the search strategy used to identify studies
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Table 1 Anticoagulation group (AC+ group, n = 8)
First
author
Country
Year
nPVR Tangential
PVR with
primary
repair
(n)
Segmental
PVR with
primary
repair
(n)
Prosthetic
grafts (n)
Vein patch or
interposition
Intra-operative
heparinization
Clamp time
(min)
SMA
inflow
occlusion
AC+ policy AC+
(n)
EPVT
(n)
Bleeding
(n)
Carrère N
France
200618
45 25 19 0 1 NR Mean 19 ± 3
(range
7–58)
Not used 1st 15 patients
therapeutic
systematic
heparin, all
others received
subcutaneous
prophylactic
LMWH
15 2 7
Smoot RL
US 200619
64 29 13 18 4 Not used Mean 14 Yes Aspirin n = 19,
Warfarin n = 11,
Clopidogrel n = 4
34 3 2
Riedinger H
Germany
200620
53 34 17 0 2 NR NR NR Systemic
therapeutic
heparin aiming
APTT 40–50 for
segmental
resection (n =
17/53), all others
received
prophylactic low
dose heparin
17 0 4
Smoot RL
US
200721
9 0 0 0 9 Not used NR Yes One patient
received
clopidogrel, and
the remainder
daily aspirin if
no clot on
post-operative
imaging. If clot
noted on
imaging systemic
heparin used.
9 0 1
Illuminati G
Italy
200822
29 15 11 0 3 Systemic
heparin
0.5 mg/kg
9 Not used LMWH for one
month followed
by aspirin
100 mg/daily
29 0 1
Ouaïssi M
France
200815
27 24 1 2 0 NR <20 Not used Systemic
therapeutic
heparin 500 U/
kg/day for 10
days followed by
warfarin for 3
months in n =
8/27; PTFE n =
2, t angential
SMV/PV
resection n = 6.
All others, n =
19/27 received
preventative
LMWH.
8 7 4
Stauffer JA
US
200914
28 1 10 10 7 Not used 18 NR Autologous PVR
had standard
perioperative
thromboprophylaxis,
PTFE grafts n =
10/28, had
thromboprophylaxis
plus low dose
warfarin 1–2 mg
for 3 months.
10 6 0
Kendrick ML
US
201123
11 6 0 0 5 Systemic
heparin
intraoperative
3000–5000
units
35 Not used Low dose aspirin
81 mg for 3
months. If
cancer or
previous
thrombosis,
warfarin given.
11 0 3
Total 266 134 71 30 31 133 (50%) 18 (7%) 22 (8%)
PVR, portal vein resection; AR, arterial resection;; SMA, superior mesenteric artery; LMWH, low-molecular-weight heparin; NR, not reported.
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correspondingly more prosthetic graft reconstructions in the AC+
group (30/61) compared with the AC− group (2/23, Fisher’s exact
P < 0.001) (Table 3).
Anticoagulation policies
There was wide variation in the published anticoagulation poli-
cies. Table 1 outlines these policies that included the use of
aspirin, clopidogrel, heparin and warfarin. In spite of the policy,
only 50% of patients in the AC+ group actually received
anticoagulation beyond described standard thromboprophylaxis.
The anticoagulation policy was evaluated in relation to the type
of venous resection and reconstruction in the AC+ group. Aspirin
was used as an anticoagulant in four centres but only in a minority
of patients (67/266, 26%) (Table 1), but this did not appear to be
related to the type of venous resection or reconstruction.19,21–23
There appeared to be a relationship between the type of graft
used for reconstruction and whether anticoagulation was advo-
cated. The AC+ group used a significantly higher proportion of
prosthetic grafts (30/61) compared with the AC− group (2/23,
Fisher’s exact P < 0.001) (Table 3).
Clinical and surgical outcomes
The overall mortality was similar in the AC+ group (12/266, 5%)
compared with the AC− group (6/95, 6% Fisher exact P = 0.583).
The overall morbidity was also similar in the AC+ group (125/266,
47%) compared with the AC− group (38/95, 40% Fisher’s exact
Table 2 No anticoagulation group (AC− group, n = 5)
First author
Country
Year
nPVR Tangential PVR
with primary
repair (n)
Segmental PVR
with primary
repair (n)
Prosthetic grafts
(n)
Vein patch or
interposition
Intra-operative
heparinization
Clamp time (min) SMA inflow
occlusion
EPVT (n)
Allema JH
Netherlands
199424
20 2 16 0 2 NR NR NR 1
Howard TJ
US
200325
13 4 6 0 3 Systemic
heparinization
(100U/kg), for
complete
isolation not side
bite clamp
NR Not used NR
Zhang J
China
200926
8 0 8 0 0 Not used Within 15 min Not used 0
Kaneoka Y
Japan
200927
42 0 27 0 15 Not used NR Yes 1
Chakravarty DK
Taiwan
201028
12 0 9 2 1 Yes NR NR NR
Total 95 6 66 2 21
PVR, portal vein resection; AR, arterial resection; NR, not reported.
Table 3 Type of pancreatic and venous resections in the AC+ and AC− group
AC+ (n = 266) AC− (n = 95) P value
Types of pancreatic resection
• Pancreaticoduodenectomy 242 (91%) 86 (91%) P = 0.223
• Total pancreatectomy 14 (5%) 9 (9%)
• Distal pancreatectomy 10 (4%)
Type of venous resection
• Tangential 147 (55%) 7 (7%) P < 0.001
• Segmental 119 (45%) 88 (93%)
Reconstruction by primary repair or anastomosis (no grafts used)
• Tangential 134/147 (91%) 6/7 P = 0.494
• Segmental 71/119 (60%) 66/88 (75%) P = 0.026
Reconstruction by grafting
• Overall (venous and prosthetic) 61/266 (23%) 23/95 (24%) P = 0.779
• Venous grafts 31/61 21/23 P < 0.001
• Prosthetic grafts 30/61 2/23 P < 0.001
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P = 0.280). When studies using prosthetic grafts were excluded in
subgroup analysis, no significant difference was found for mor-
tality (AC+ 5/147, 3% versus AC− 6/83, 7% Fisher’s exact P =
0.211) or morbidity (AC+ 63/147, 43% versus AC− 32/83, 39%
Fisher’s exact P = 0.578).
The incidence of reoperations and bleeding was not reported by
all the studies and were analysed in studies that reported these
outcomes. The incidence of re-operations was similar in the
reported studies in the AC+ group (n = 6, 23/225, 10%) compared
with the AC− group (n = 3, 6/75, 8% Fisher’s exact test P = 0.658)
The incidence of bleeding in the reported studies was lower in
the AC+ group (n = 8, 22/266, 8%) compared with the AC− group
(n = 2, 7/32, Fisher’s exact test P = 0.025) (Table 4).
Early portal venous thrombosis
There was a higher incidence of EPVT reported in the AC+ group
(n = 9, 18/266, 7%) compared with the AC− group (n = 3, 2/70, 3%
Fisher’s exact P = 0.270). The overall mortality associated with
EPVT was 40% (8/20). The mortality associated with EPVT was
similar in the AC+ group (7/18) compared with the AC− group
(1/2, Fisher’s exact P = 1.000).
The incidence of EPVT was also examined in relation to the
type of resection and reconstruction. The type of vascular recon-
struction was described for 19 of the 20 EPVT. In the AC + group
there were comparable rates of EPVT in those who had a tangen-
tial resection (8/147, 5%) compared with a segmental resection
(10/119, 8%, Fisher’s exact test P = 0.462). There were also similar
EPVT from a primary closure (13/205, 6%) compared with graft-
ing (5/61, 8% Fisher’s exact P = 0.571). There were more EPVT in
prosthetic grafts (4/30) compared with vein grafts (1/31, Fisher’s
exact P = 0.195).
When studies that used prosthetic grafts were excluded from
analysis, there was no difference in the incidence of EPVT in the
AC+ group (2/147) compared with the AC− group (2/83, Fisher’s
exact test P = 0.621).10,11,15,24
Discussion
There is no agreed approach to anti-coagulation after a venous
resection with a pancreatic resection in the published literature.
This reflects the absence of high-level evidence and evidence-
based guidelines. This review found that in centres with an anti-
coagulation policy only half of the patients received it, which
made it difficult to derive firm conclusions about outcomes
when comparing outcomes with centres that had no such policy.
This difficulty was further compounded by differences in
anticoagulation policy and also variations in the types of venous
resection and reconstruction. There were higher proportions of
patients having tangential (c.f. segmental) venous resections
and prosthetic (c.f. venous) grafts in the group that had an
anticoagulation policy. It was found that there was no difference
between both anticoagulation groups, as implemented, in terms of
overall morbidity and mortality. Early portal vein thrombosis was
more common in the group with an anticoagulation policy (7%
versus 3%), in those have prosthetic graft reconstruction (13%
versus 3%) and this was associated with 40% mortality.
Portal vein reconstruction is performed mostly in the setting
of liver transplantation where anticoagulation is not routinely
given, and EPVT is seen far less frequently than hepatic artery
thrombosis (2% versus 9%). The incidence of vascular thrombo-
sis in this group has been shown to be related to high fibrinogen
levels, and low protein C levels suggesting future anticoagulation
trials may be warranted in this high-risk group.29 Anticoagulation
has been shown to be safe and in paediatric liver transplantation
has been shown to reduce early thrombotic events.30,31 In contrast
to pancreatic surgery, there is tendency to antoanticoagulation
in liver transplantation particularly after liver reperfusion.32 In
contrast, there is tendency to procoagulation in patients with
pancreatic cancer undergoing a pancreatectomy and venous
resection.33
Early portal vein thrombosis occurred more frequently in the
AC+ group, and interestingly, there were a higher proportion of
tangential resections and fewer segmental resections compared
with the AC− group. Tangential resections can be associated with
a degree of luminal narrowing that can be avoided with a trans-
verse repair or a patch graft, and historically this was advocated
when the degree of luminal narrowing was more than one-third
of the venous circumference. In this review, EPVT was not more
likely with tangential or segmental resections in AC+ group.
However, EPVT did occur more frequently with prosthetic grafts
in our study (4/30, 13%) and this incidence is similar to a study
by Chu et al. (3/33, 9%) in which PTFE grafts were used.
Echoing the high mortality of 40% with EPVT in this review, the
study by Chu et al. reported a mortality of 33%.34 When pros-
thetic grafts were excluded, there was no difference in EPVT
between the AC+ group and the AC− group.
Table 4 Overall morbidity, reoperations, bleeding and mortality in the AC+ and AC− group
AC+ (n = 266) AC− (n = 95) P-value
Mortality 12/266 (5%) 6/95 (6%) P = 0.583
Overall morbidity 125/266 (47%) 38/95 (40%) P = 0.280
Reoperations 23/225 (10%)
*n = 6 studies reported outcome
6/75 (8%)
*n = 3 studies reported outcome
P = 0.658
Bleeding 22/266 (8%)
*n = 8 studies reported outcome
7/32
*n = 2 studies reported outcome
P = 0.025
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The need for interposition grafts is debated as several centres
report successful direct end-to-end venous anastomosis even
when the length of the resected vein is up to 5 cm. Several previ-
ous studies have shown that an adequate length of SMV/PV can be
achieved with adequate mobilization of the root of mesentery and
dividing the ligaments of the liver as well to enable a primary
end-to-end anastomosis and obviating the need for an interposi-
tion graft.35
Early portal vein thrombosis can also be caused by technical
factors. In the Carrere study, two cases of EPVT were thought to be
the result of technical factors. In one the venous anastomosis was
twisted, and flow was successfully re-established by re-operation,
and in the other the narrow diameter anastomosis led to
mesenteric infarction. Stauffer et al. hypothesised that their four
cases of EPVT after a segmental resection may have been due to
the lack of expansion of the anastomosis or increased anastomotic
tension upon return of the bowel and closure of the abdomen.
Surgical technique during venous anastomosis requires provision
of a ‘growth factor’ to enable adequate venous expansion upon
re-establishing blood flow.
Before anticoagulation is dismissed on the basis that this
review has been unable to demonstrate a benefit for it, there are
several factors that need to be considered. First, only 50% of
patients in the AC+ group received anticoagulation beyond
standard peri-operative thromboprophylaxis. Second, the use of
standard thromboprophylaxis in these studies was not controlled
for and the effect due to this could not be accounted for in this
review. Thirdly, there was a higher frequency of vein and pros-
thetic grafts in the AC+ group. These factors mean that a firm
conclusion about anticoagulation in this setting cannot be drawn
from the available data. This highlights the need for better
designed studies on which to determine an evidence-based policy
for the use of anticoagulation in this setting. This is now more
important with the increased use of venous resection with
pancreatectomy.
In conclusion this review demonstrates highly variable prac-
tice with the use of anticoagulation after venous resection with a
pancreatectomy. The data heterogeneity makes it impossible to
perform a formal meta-analysis. As we do not know what policy
should be instituted in this setting, there is equipoise regarding
anticoagulation and this should provide a strong impetus for a
well-designed, multi-centre randomized controlled trial. Such a
study should include standardized definitions to describe the
types of vascular resection (e.g. Type 1 – Tangential resection
and Type 2 – Segmental resection) and reconstruction tech-
niques (e.g. a. Primary venous anastomosis, b. venous graft, c.
prosthetic graft use). The data from this review indicate that
early portal vein thrombosis still occurs, is four times more likely
after prosthetic graft reconstruction and is associated with a 40%
mortality.
Conflicts of interest
There are no sources of funding to disclose.
References
1. Warshaw AL, Gu Z, Wittenberg J, Waltmann AC. (1990) Preoperative
staging and assessment of resectability of pancreatic cancer. Arch Surg
125:230–233.
2. Warshaw AL, Castillo CF. (1992) Pancreatic carcinoma. N Engl J Med
362:455–465.
3. Siriwardana HPP, Siriwardena AK. (2006) Systematic review of outcome
of synchronous portal-superior mesenteric vein resection during pan-
createctomy for cancer. Br J Surg 93:662–673.
4. Chua TC, Saxena A. (2010) Extended Pancreaticoduodenectomy with
vascular resection for pancreatic cancer: a systematic review. J
Gastrointest Surg 14:1442–1452.
5. Tseng JF, Raut CP, Lee JE, Pisters PWT, Vauthey J, Abdalla EK et al.
(2004) Pancreaticoduodenectomy with vascular resection: margin status
and survival duration. J Gastrointest Surg 8:935–949.
6. Christians KK, Lal A, Pappas S, Quebbeman E, Evans DB. (2010) Portal
vein resection. Surg Clin N Am 90:309–322.
7. Banz VM, Croagh D, Coldham C, Tanière P, Buckels J, Isaac J et al. (2012)
Factors influencing outcome in patients undergoing portal vein resection
for adenocarcinoma of the pancreas. Eur J Surg Oncol 38:72–79.
8. Zhou Y, Zhang Z, Liu Y, Li B, Xu D. (2012) Pancreatectomy combined
with superior mesenteric vein-portal vein resection for pancreatic cancer:
a meta-analysis. World J Surg 36:884–891.
9. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L,
Linehan DC. (2009) Pretreatment assessment of resectable and border-
line resectable pancreatic cancer: expert consensus statement. Ann Surg
Oncol 16:1727–1733.
10. Sanjay P, Takaori K, Govil S, Shrikhande SV, Windsor JA. (2012) ‘Artery-
first’ approaches to pancreatoduodenectomy. Br J Surg 99:1027–1035.
11. Nakao A, Takeda S, Inoue S, Nomoto S, Kanazumi N, Sugimoto H et al.
(2006) Indications and technique of extended resection for pancreatic
cancer. World J Surg 30:976–982.
12. Li B, Chen FZ, Ge XH, Cai MZ, Jiang JS, Li JP et al. (2004)
Pancreatoduodenectomy with vascular reconstruction in treating carci-
noma of the pancreatic head. Hepatobiliary Pancreat Dis Int 3:612–615.
13. Leach SD, Lee JE, Charnsangavej C, Cleary KR, Lowy AM, Fenoglio CJ
et al. (1998) Survival following pancreaticoduodenectomy with resection
of the superior mesenteric-portal vein confluence for adenocarcinoma of
the pancreatic head. Br J Surg 85:611–617.
14. Stauffer JA, Dougherty MK, Kim GP, Nguyen JH. (2009) Interposition
graft with polytetrafluoroethylene for mesenteric and portal vein recon-
struction after pancreaticoduodenectomy. Br J Surg 96:247–252.
15. Ouaïssi M, Sielezneff I, Pirro N, Bon Mardion R, Chaix JB, Merad A et al.
(2008) Therapeutic anticoagulant does not modify thromboses rate vein
after venous reconstruction following pancreaticoduodenectomy.
Gastroenterol Res Pract 2008:896320.
16. Moher D, Liberati A, Tetzlaff J, Altman DG. (2009) Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA statement.
J Clin Epidemiol 62:1006–1012.
17. Lai ECS. (2012) Vascular resection and reconstruction at pancreaticoduo-
denectomy: technical issues. Hepatobiliary Pancreat Dis Int 11:234–242.
18. Carrère N, Sauvanet A, Goere D, Kianmanesh R, Vullierme MP, Couvelard
A et al. (2006) Pancreaticoduodenectomy with mesentericoportal vein
resection for adenocarcinoma of the pancreatic head. World J Surg
30:1526–1535.
19. Smoot RL, Christein JD, Farnell MB. (2006) Durability of portal venous
reconstruction following resection during pancreaticoduodenectomy.
J Gastrointest Surg 10:1371–1375.
HPB 697
HPB 2014, 16, 691–698 © 2013 International Hepato-Pancreato-Biliary Association
20. Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT. (2006) Postop-
erative morbidity and long-term survival after pancreaticoduodenectomy
with superior mesenterico-portal vein resection. J Gastrointest Surg
10:1106–1115.
21. Smoot RL, Christein JD, Farnell MB. (2007) An innovative option for
venous reconstruction after ancreaticoduodenectomy: the left renal vein.
J Gastrointest Surg 11:425–431.
22. Illuminati G, Carboni F, Lorusso R, D'Urso A, Ceccanei G,
Papaspyropoulos C et al. (2008) Results of a pancreatectomy with a
limited venous resection for pancreatic cancer. Surg Today 38:517–523.
23. Kendrick ML, Sciabas GM. (2011) Major venous resection during total
laparoscopic pancreaticodeuodenectomy. HPB 13:454–458.
24. Allema JH, Reinders ME, van Gulick TM, van Leeuwen DJ, de Wit LT,
Verbeek PC et al. (1994) Portal vein resection in patients undergoing
pancreatoduodenectomy for carcinoma of the pancreatic head. Br J Surg
81:1642–1646.
25. Howard TJ, Villanustre N, Moore SA, DeWitt J, LeBlanc J, Maglinte D
et al. (2003) Efficacy of venous reconstruction in patients with adenocar-
cinoma of the pancreatic head. J Gastrointest Surg 7:1089–1095.
26. Zhang J, Qian HG, Leng JH, Cui M, Qiu H, Zhou GQ et al. (2009) Long
mesentericoportal vein resection and end-to-end anastomosis without
graft in pancreaticoduodenectomy. J Gastrointest Surg 13:1524–1528.
27. Kaneoka Y, Yamaguchi A, Isogai M. (2009) Portal or superior mesenteric
vein resection for pancreatic head adenocarcinoma: prognostic value of
the length of venous resection. Surgery 145:417–425.
28. Chakravarty KD, Hsu JT, Liu KH, Yeh CN, Yeh TS, Hwang TL et al. (2010)
Prognosis and feasibility of en-bloc vascular resection in stage II pancre-
atic adenocarcinoma. World J Gastroenterol 16:997–1002.
29. Ayala R, Martínez-López J, Cedena T, Bustelos R, Jimenez C, Moreno E
et al. (2011) Recipient and donor thrombophilia and the risk of portal
venous thrombosis and hepatic artery thrombosis in liver receipients.
BMC Gastroenterol 11:130.
30. Widén A, Rolando N, Manousou P, Rolles K, Davidson B, Sharma D et al.
(2009) Anticoagulation after liver transplantation: a retrospective audit
and case-control study. Blood Coagul Fibrinolysis 20:615–618.
31. McLin VA, Rimensberger P, Belli DC, Wildhaber BE. (2011)
Anticoagulation following pediatric liver transplantation reduces early
thrombotic events. Pediatr Transplant 15:117–118.
32. Senzolo M, Burra P, Cholongitas E, Burroughs AK. (2006) New insights
into the coagulopathy of liver disease and liver transplantation. World J
Gastroenterol 28:7725–7736.
33. Khorana AA, Fine RL. (2004) Pancreatic cancer and thromboembolic
disease. Lancet Oncol 5:655–663.
34. Chu CK, Farnell MB, Nguyen JH, Stauffer JA, Kooby DA, Sclabas GM
et al. (2010) Prosthetic graft reconstruction after portal vein resection in
pancreaticoduodenectomy: a multicenter analysis. J Am Coll Surg
211:316–324.
35. Wang F, Arianayagam R, Gill A, Puttaswamy V, Neale M, Gananadha S
et al. (2012) Grafts for mesenterico-portal vein resections can be avoided
during pancreaticoduodenectomy. J Am Coll Surg 215:569–579.
698 HPB
HPB 2014, 16, 691–698 © 2013 International Hepato-Pancreato-Biliary Association
